miR-301a expression: Diagnostic and prognostic marker for prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Prostate-specific antigen (PSA) screening for prostate cancer (CaP) lacks definitive diagnostic power.
• There is a need for reliable biomarkers to differentiate between benign prostate hyperplasia (BPH) and clinically significant CaP.
• MicroRNA 301a (miR-301a) is investigated as a potential supplemental biomarker for CaP detection and risk stratification.

Purpose of the Study:

• To establish miR-301a as a biomarker for distinguishing CaP from BPH.
• To evaluate the predictive value of miR-301a for adverse CaP pathology.
• To elucidate the molecular mechanisms underlying miR-301a's role in CaP progression.

Main Methods:

• Serum and tumor samples from BPH and CaP patients (Gleason scores 6 and 7) were analyzed.
• Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to detect miR-301a expression.
• In vitro studies, including cell viability assays and Western blots, were performed to understand miR-301a's molecular function.

Main Results:

• miR-301a expression was significantly higher in both serum and tumor tissues of CaP patients compared to BPH patients (P = 0.011 and 0.013).
• miR-301a levels correlated positively with increased Gleason scores in prostatectomy specimens.
• miR-301a was found to inhibit the pro-apoptotic protein RUNX3 and activate the pro-survival pathway mediated by ROCK1 in CaP cells.

Conclusions:

• miR-301a serves as a valuable adjunct biomarker for stratifying patients with elevated PSA and those diagnosed with CaP.
• Incorporating miR-301a into clinical decision-making tools, such as the MSKCC post-prostatectomy nomogram, enhances their predictive accuracy.
• miR-301a's role in regulating apoptosis and survival pathways highlights its significance in CaP pathogenesis.